- Home
- TGB vs IMTX Comparison
TGB vs IMTX Comparison
Compare TGB & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- IMTX
- Stock Information
- Founded
- TGB 1966
- IMTX N/A
- Country
- TGB Canada
- IMTX Germany
- Employees
- TGB N/A
- IMTX N/A
- Industry
- TGB Precious Metals
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TGB Basic Materials
- IMTX Health Care
- Exchange
- TGB Nasdaq
- IMTX Nasdaq
- Market Cap
- TGB 698.1M
- IMTX 579.8M
- IPO Year
- TGB N/A
- IMTX N/A
- Fundamental
- Price
- TGB $2.81
- IMTX $5.61
- Analyst Decision
- TGB
- IMTX Strong Buy
- Analyst Count
- TGB 0
- IMTX 4
- Target Price
- TGB N/A
- IMTX $14.67
- AVG Volume (30 Days)
- TGB 14.3M
- IMTX 754.4K
- Earning Date
- TGB 07-30-2025
- IMTX 08-12-2025
- Dividend Yield
- TGB N/A
- IMTX N/A
- EPS Growth
- TGB N/A
- IMTX N/A
- EPS
- TGB N/A
- IMTX N/A
- Revenue
- TGB $417,640,101.00
- IMTX $155,801,989.00
- Revenue This Year
- TGB $22.13
- IMTX N/A
- Revenue Next Year
- TGB $36.13
- IMTX $1.92
- P/E Ratio
- TGB N/A
- IMTX N/A
- Revenue Growth
- TGB 7.89
- IMTX 93.56
- 52 Week Low
- TGB $1.67
- IMTX $3.30
- 52 Week High
- TGB $3.14
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- TGB 58.69
- IMTX 51.00
- Support Level
- TGB $2.85
- IMTX $5.90
- Resistance Level
- TGB $3.02
- IMTX $6.38
- Average True Range (ATR)
- TGB 0.15
- IMTX 0.39
- MACD
- TGB 0.01
- IMTX -0.05
- Stochastic Oscillator
- TGB 60.59
- IMTX 16.30
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.